Mersana Therapeutics to Present Interim Phase 1 Data on XMT-1522 at the 2018 American Society of Clinical Oncology Annual Meeting

May 22, 2018
Conference Call Featuring Principal Investigator Erika Hamilton, MD to be Held Monday, June 4, 2018, at 6:30 pm CDT

CAMBRIDGE, Mass., May 22, 2018 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody drug conjugates (ADCs) based on its Dolaflexin and other proprietary platforms, today announced that it will present interim data from the ongoing Phase 1 dose-escalation and expansion study evaluating the company’s investigational compound, XMT-1522, in patients with HER2-expressing breast, lung and gastric tumors. The data will be presented in a poster session at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, IL.

Details of the poster presentation are as follows:

Title: Phase 1 dose escalation of XMT-1522, a novel HER2-targeting antibody-drug conjugate (ADC), in patients (pts) with HER2-expressing breast, lung and gastric tumors.
Abstract Number: 2546
Poster Session: Developmental Therapeutics—Clinical Pharmacology and Experimental Therapeutics
Date
: June 4, 2018
Time: 8:00 – 11:30 a.m. (CDT)
Presenters:Erika Hamilton, MD, Director, Breast and Gynecologic Cancer Research Program, Sarah Cannon Research Institute and Eric Hailman, Senior Medical Director at Mersana Therapeutics

Mersana will also host a conference call and webcast including principal investigator, Erika Hamilton, MD, on Monday, June 4, 2018, at 6:30 p.m. CDT to discuss the data being presented at ASCO.

To access the call, please dial (877) 876-9177 and provide the Conference ID Mersana. A live webcast of the presentation will be available on the Investors & Media section of the Mersana website at www.mersana.com.

About Mersana Therapeutics

Mersana Therapeutics is a clinical-stage biopharmaceutical company using its differentiated and proprietary ADC platforms to develop highly targeted drugs with increased tolerability and expanded opportunities to deliver meaningful clinical benefit to patients.  Mersana’s product candidate XMT-1522 is in Phase 1 clinical trials in patients with advanced tumors expressing HER2, including breast cancer, non-small-cell-lung-cancer (NSCLC) and gastric cancer. The Company’s second product candidate, XMT-1536, is in Phase 1 clinical trials in patients with tumors expressing NaPi2b, including ovarian cancer, NSCLC and other cancers. In addition, multiple partners are using Mersana’s platform to advance their ADC pipelines.

Media Contact
Paul Kidwell
pkidwell@mersana.com
617-680-1088

Investor Contact
Stern Investor Relations, Inc.
Christina Tartaglia
christina@sternir.com
(212) 362-1200

 

Primary Logo

Source: Mersana Therapeutics, Inc.